Skip to content
The Nexus
BUSINESSJul 27 · 12:00 UTCQUARTZCris Tolomia

AstraZeneca's profit beat expectations as cancer drug sales powered growth

AstraZeneca's core earnings per share increased to $2.63 in Q2, exceeding analyst expectations of $2.48. The company attributed the growth to strong cancer drug sales and maintained its full-year and 2030 outlooks.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned
AstraZenecaorganizationcancer drug salestopiccore earnings per sharetopicanalyst expectationstopic
Spot something wrong with this article?Report a problem →
Forward this
Related Signal

Adjacent reporting